Overview
Jena Sold is of counsel in the Litigation practice of Paul Hastings and is based in the firm's New York office. She represents corporations and individual officers in both internal and government investigations, including investigations by the Department of Justice, Securities and Exchange Commission, and other regulatory agencies. Ms. Sold has conducted investigations across industries, with particular focus on the life sciences sector. Her extensive experience in international anti-corruption and the Foreign Corrupt Practices Act (FCPA) includes conducting risk assessments, transactional anti-corruption due diligence and integration, and investigations throughout Europe, Asia, and Latin America.
Education
- Emory University School of Law, J.D. (with honors, Order of the Coif, Executive Managing Editor Emory Law Journal)
- Cornell University, B.S.
Representations
Investigations and White Collar Defense
- Represents a former senior officer of a public company in trials involving allegations of accounting and securities fraud, including a criminal trial brought by the U.S. Attorney’s Office for the District of Delaware
- Conducting internal investigations on behalf of a large insurance company relating to allegations of Medicare Risk Adjustment fraud in violation of the False Claims Act
- Conducting internal investigation on behalf of a multi-national pharmaceutical company relating to allegations of potential expense inflation and falsification by third-party vendor in violation of the FCPA in the Philippines
- Conducted internal investigation on behalf of a multi-national pharmaceutical company relating to kickback allegations in the Philippines
- Represented a Middle Eastern service provider in the oil and gas industry in an investigation by the Department of Justice and Securities and Exchange Commission relating to bribery allegations
- Represented a foreign exchange trader in connection with an investigation by the Department of Justice into alleged currency market manipulation related to swaptions trading
- Represented individuals in trading and sales at an international bank in connection with an investigation by the Department of Justice into alleged manipulation of foreign exchange rates through collusion
- Represented the Board member of a health sciences company in an investigation by the Securities & Exchange Commission for insider trading
Risk Assessments, Diligence, and Compliance
- Conducting a global risk assessment, and enhancing and implementing a global compliance program, for a multi-national pharmaceutical company
- Represented numerous multi-national pharmaceutical companies in global anti-bribery and anti-corruption due diligence and integration efforts associated with multi-billion dollar transactions
- Conducted anti-bribery and anti-corruption due diligence review of the Brazilian business of a multi-national pharmaceutical company in connection with a multi-billion dollar acquisition, divestiture, and joint venture transaction
- Conducted anti-bribery and anti-corruption due diligence review of the Philippines business of a multi-national pharmaceutical and medical device company in connection with a multi-billion dollar acquisition
- Conducted anti-bribery and anti-corruption due diligence review of the South Korean and Turkish businesses of a multi-national orphan drug company in connection with a multi-billion dollar acquisition
- Counseled multi-national pharmaceutical company on enhancements to their third-party program and policies and procedures based on analysis of their compliance investigations docket
news
Recognitions
insights
- Compliance in the Era of COVID-19 – Where and How Life Sciences and Health Care Companies Should Focus in the Era of Social Distancing - April 22nd, 2020
- It’s Back—True to the Promise of Continued Scrutiny of Life Sciences, the SEC Enters a $25M FCPA Resolution with Novartis - April 6th, 2016
- It Keeps Going and Going and Going—Second Circuit Reaffirms Stringent Scienter Standard for Securities Fraud Claim Against Auditors of Battery Company - March 27th, 2015
Engagement & Publications
- It’s Back—True to the Promise of Continued Scrutiny of Life Sciences, the SEC Enters a $25M FCPA Resolution with Novartis, Stay Current, April 6, 2016
- It Keeps Going and Going and Going—Second Circuit Reaffirms Stringent Scienter Standard for Securities Fraud Claim Against Auditors of Battery Company, Stay Current, March 27, 2015